Genotyping Assay Market Report 2026

Genotyping Assay Market Overview

• Genotyping Assay market size has reached to $41.31 billion in 2025 • Expected to grow to $116.09 billion in 2030 at a compound annual growth rate (CAGR) of 22.9% • Growth Driver: Rising Genetic Disorder Prevalence Drives Growth in the Genotyping Assay Market • Market Trend: CE-IVD Marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit For Treatment-Resistant Strains Of HIV-1 • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Genotyping Assay Market?

A genotyping assay is a laboratory technique or method used to determine an individual's genetic makeup at specific genetic loci or positions within their DNA. It identifies and analyzes genetic variations, such as single nucleotide polymorphisms (SNPs) or insertions or deletions, that exist in an individual's genome. The main products and services in the genotyping assay are reagents and kits, genotyping services, instruments, and bioinformatics. Reagents and kits are essential components in various scientific and laboratory processes, particularly in fields like molecular biology, chemistry, and diagnostics. The various technologies include microarrays, polymerase chain reaction, sequencing, capillary electrophoresis, matrix-assisted laser desorption or ionization-time of flight mass spectrometry, and others used by various end-users such as pharmacogenomics, personalized medicine and diagnostics, animal genetics, agricultural biotechnology, research and diagnostic laboratories, and academic institutes.

What Is The Genotyping Assay Market Growth Forecast?

The genotyping assay market size is expected to see exponential growth in the next few years. It will grow to $116.09 billion in 2030 at a compound annual growth rate (CAGR) of 22.9%. The growth in the forecast period can be attributed to increased biomarker-driven drug development, automation in laboratories, expansion of companion diagnostics, demand for rapid assays, regulatory validation. Major trends in the forecast period include rising demand for snp-based assays, increased adoption of pcr-based genotyping, growth of high-sensitivity genotyping assays, expansion of genotyping assays in drug development, integration of automation in assay processing.

What Is The Driver Of The Genotyping Assay Market?

The increasing prevalence of genetic disorders is expected to propel the growth of the genotyping assay market going forward. Genetic disorders are a group of medical conditions that are caused by abnormalities or mutations in an individual's deoxyribonucleic acid (DNA). Genotyping assays compare the DNA of affected people to that of healthy people to spot changes and can reveal specific genetic mutations or variations linked to a particular genetic disorder. For instance, in June 2023, Gene People, a UK-based registered charity organization supporting individuals with genetic conditions, reported that one in every 25 children in the UK had a genetic disorder, affecting approximately 30,000 newborns and young children in the country as well as more than 2.4 million children and adults annually. Therefore, the increasing prevalence of genetic disorders is driving the growth of the genotyping assay industry.

Key Players In The Global Genotyping Assay Market

Major companies operating in the genotyping assay market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, BGI Genomics, LGC Biosearch Technologies, GenScript Biotech, Promega Corporation, Luminex Corporation, Integrated DNA Technologies Inc., 23andMe Inc., Novogene Corporation, Oxford Nanopore Technologies plc, GenMark Diagnostics Inc., Macrogen Inc., Pacific Biosciences of California Inc., Standard BioTools Inc., Genewiz Inc., New England Biolabs

Global Genotyping Assay Market Trends and Insights

Major companies operating in the genotyping assay market are developing advancements in genomic research such as CE-IVD marked assay to detect treatment-resistant strains of HIV-1. CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit refers to a Sanger sequencing-based assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that may resist common antiretroviral therapeutics. For instance, in January 2023, Thermo Fisher Scientific, a US-based company launched CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit. This system detects treatment-resistant strains of HIV-1 and has unique features that include assessing genomic mutations, using HIV RNA, detecting drug resistance mutations, using gold-standard Sanger sequencing technology, and is designed for clinical use. The launch of the Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit has added value by improving the detection of treatment-resistant HIV-1 strains, providing ready-to-use reagents and controls, meeting regulatory requirements, having high-performance characteristics, and being compatible with existing sequencing platforms and workflows.

What Are Latest Mergers And Acquisitions In The Genotyping Assay Market?

In August 2023, Transnetyx Inc., a US-based biotechnology company acquired Laragen Inc. for an undisclosed sum. With this acquisition, Transnetyx hopes to expand its offering of solutions to include sequencing and next-generation sequencing (NGS) services, giving large research institutes better access to cutting-edge genetic services. Laragen Inc. is a US-based biotechnology company that provides sequencing and genotyping assay services for DNA.

What Defines the Genotyping Assay Market?

The genotyping assay market includes revenues earned by entities that provide genotyping assay services such as single nucleotide polymorphisms (SNPs) genotyping, short tandem repeats (STRs) genotyping, whole genome genotyping, and clinical genotyping services. The market value includes the value of related goods sold by the service provider or included within the service offering. The genotyping assay market consists of sales of products such as polymerase chain reaction (PCR) primers, SNP genotyping kits, DNA extraction kits, and microarray chips. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Genotyping Assay Market Report 2026?

The genotyping assay market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the genotyping assay industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.